B-cell-derived lymphotoxin promotes castration-resistant prostate cancer - PubMed
- ️Fri Jan 01 2010
B-cell-derived lymphotoxin promotes castration-resistant prostate cancer
Massimo Ammirante et al. Nature. 2010.
Abstract
Prostate cancer (CaP) progresses from prostatic intraepithelial neoplasia through locally invasive adenocarcinoma to castration-resistant metastatic carcinoma. Although radical prostatectomy, radiation and androgen ablation are effective therapies for androgen-dependent CaP, metastatic castration-resistant CaP is a major complication with high mortality. Androgens stimulate growth and survival of prostate epithelium and early CaP. Although most patients initially respond to androgen ablation, many develop castration-resistant CaP within 12-18 months. Despite extensive studies, the mechanisms underlying the emergence of castration-resistant CaP remain poorly understood and their elucidation is critical for developing improved therapies. Curiously, castration-resistant CaP remains androgen-receptor dependent, and potent androgen-receptor antagonists induce tumour regression in castrated mice. The role of inflammation in castration-resistant CaP has not been addressed, although it was reported that intrinsic NF-kappaB activation supports its growth. Inflammation is a localized protective reaction to injury or infection, but it also has a pathogenic role in many diseases, including cancer. Whereas acute inflammation is critical for host defence, chronic inflammation contributes to tumorigenesis and metastatic progression. The inflammation-responsive IkappaB kinase (IKK)-beta and its target NF-kappaB have important tumour-promoting functions within malignant cells and inflammatory cells. The latter, including macrophages and lymphocytes, are important elements of the tumour microenvironment, but the mechanisms underlying their recruitment remain obscure, although they are thought to depend on chemokine and cytokine production. We found that CaP progression is associated with inflammatory infiltration and activation of IKK-alpha, which stimulates metastasis by an NF-kappaB-independent, cell autonomous mechanism. Here we show that androgen ablation causes infiltration of regressing androgen-dependent tumours with leukocytes, including B cells, in which IKK-beta activation results in production of cytokines that activate IKK-alpha and STAT3 in CaP cells to enhance hormone-free survival.
Figures

Six week old FVB males (n=10) were inoculated with myc-CaP cells. When tumors reached 1000 mm3, mice were left untreated, castrated or sham operated. Tumors were collected when indicated for analysis. A. Paraffin-embedded tumor sections were TUNEL stained to determine apoptotic cell frequency (results are averages, n=3). B. Total RNA was isolated from tumor samples and expression of indicated cell marker mRNAs was quantitated and normalized to that of cyclophilin A (norm= normal, C1,2,3= mice analyzed 1,2,3 weeks after castration, sham= sham-operated). Results are averages ± s.d. (n=10). C. Frozen human prostate sections (normal tissue [n=3], prostatic hyperplasia [n=3], and malignant CaP with Gleason scores 6-8 [n=10]) were stained with CD4, CD8 and CD20 antibodies and DAPI and analyzed by immunofluorescent microscopy. The histogram denotes average frequencies of indicated cell types (n=3 per sample). P values were determined and are depicted as insignificant (ns), significant (*), very significant (**) or highly significant (***).

A. Myc-CaP tumors were established in WT mice reconstituted with BM from Rag1−/− males (n=10) or in Rag1−/− males. When tumors reached 1000 mm3, mice were castrated. Three days before castration, Rag1−/− mice (n=10 per group) received via the tail vein purified splenic B or T cells. Tumor volume was measured. Results are averages ± s.e.m.. P values were determined and are indicated as above. B. Tumors were removed from radiation chimeras reconstituted with IkkβF/F, IkkβΔ/Δ, or Rag1−/− BM, one week after castration. STAT3 phosphorylation was analyzed by immunohistochemistry. C. Tumor-bearing Rag1−/− males were injected with WT splenocytes (Rag1 + WT), or purified splenic B (Rag1 + B) or T (Rag1 + T) lymphocytes. One day later, mice were castrated and after one week, tumors were removed and analyzed for STAT3 phosphorylation.

Tumor-bearing mice were castrated or sham operated as above. A. Tumors were analyzed one week later for nuclear IKKα by immunohistochemistry. B. Tumors removed at indicated times were divided into cytosolic (C) and nuclear (N) fractions and IKKα and histone H3 distribution was determined. C. Tumors were established using myc-CaP cells transduced with lentiviruses expressing scrambled siRNA (sc) or IKKα-specific siRNA. Mice were castrated as above and tumor volume was measured. Results are averages ± s.e.m. (n=10). P values were determined and are indicated as above. D. Tumors were established in lethally irradiated FVB males reconstituted with IkkβF/F or IkkβΔ/Δ BM or in Rag1−/− males reconstituted with either B or T cells. IkkβF/F and IkkβΔ/Δ chimeras were i.p. injected three times with poly(IC) (250 μg) prior to castration to delete IKKβ. One week after castration, tumor samples were analyzed for IKKα distribution by immunohistochemistry. Nuclear IKKα results in punctuate staining, while cytoplasmic IKKα results in diffuse staining.

A. RNA from splenic B cells of IkkβF/F and IkkβΔ/Δ mice was analyzed for LTα and LTβ expression as above. Results are averages ± s.d. (n=3). B. Lethally irradiated FVB males were reconstituted with BM from B-Ltβ−/− or T-Ltβ−/− mice (n=6 per group). After 8 weeks, myc-CaP tumors were established, mice were castrated and tumor volume was measured as above. Results are averages ± s.e.m.. C. FVB mice (n=6 each group) bearing myc-CaP tumors were castrated and given hIgG or LTβR-Ig (100 μg) every 5 days, starting 4 days before castration. Tumor volume was measured as above. Results are averages ± s.e.m.. D. Tumors were established using myc-CaP cells transduced with lentiviruses expressing scrambled (sc) siRNA or LTβ-specific siRNA. Mice were castrated and tumor volume was measured. Results are averages ± s.e.m. (n=10). E. Myc-CaP cells (previously infected with lentiviruses expressing scrambled or IKKα siRNAs) were plated at 40% confluency. After 6 hrs, the cells were cultured with or without flutamide (10 μM) in the absence or presence of LTα2β1, and cell number was determined. F. Myc-CaP cells were plated at 60% confluency. After 12 hrs, cells were stimulated for 1 hr with LTα2β1, collected, divided into cytosolic (C) and nuclear (N) fractions and IKKα and histone H3 distribution was determined. In A, B, C, D and E, P values were determined and are indicated as above.
Similar articles
-
Joseph IB, Nelson JB, Denmeade SR, Isaacs JT. Joseph IB, et al. Clin Cancer Res. 1997 Dec;3(12 Pt 1):2507-11. Clin Cancer Res. 1997. PMID: 9815654
-
Rodríguez-Berriguete G, Fraile B, Paniagua R, Aller P, Royuela M. Rodríguez-Berriguete G, et al. Prostate. 2012 Jan;72(1):40-50. doi: 10.1002/pros.21404. Epub 2011 Apr 25. Prostate. 2012. PMID: 21520161
-
Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin.
Luo JL, Tan W, Ricono JM, Korchynskyi O, Zhang M, Gonias SL, Cheresh DA, Karin M. Luo JL, et al. Nature. 2007 Apr 5;446(7136):690-4. doi: 10.1038/nature05656. Epub 2007 Mar 18. Nature. 2007. PMID: 17377533
-
Nguyen DP, Li J, Yadav SS, Tewari AK. Nguyen DP, et al. BJU Int. 2014 Aug;114(2):168-76. doi: 10.1111/bju.12488. Epub 2014 Feb 20. BJU Int. 2014. PMID: 24215139 Review.
-
Shiota M, Yokomizo A, Naito S. Shiota M, et al. Free Radic Biol Med. 2011 Oct 1;51(7):1320-8. doi: 10.1016/j.freeradbiomed.2011.07.011. Epub 2011 Jul 23. Free Radic Biol Med. 2011. PMID: 21820046 Review.
Cited by
-
Prostate carcinogenesis: inflammatory storms.
de Bono JS, Guo C, Gurel B, De Marzo AM, Sfanos KS, Mani RS, Gil J, Drake CG, Alimonti A. de Bono JS, et al. Nat Rev Cancer. 2020 Aug;20(8):455-469. doi: 10.1038/s41568-020-0267-9. Epub 2020 Jun 16. Nat Rev Cancer. 2020. PMID: 32546840 Review.
-
Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity.
Germain C, Gnjatic S, Dieu-Nosjean MC. Germain C, et al. Front Immunol. 2015 Feb 23;6:67. doi: 10.3389/fimmu.2015.00067. eCollection 2015. Front Immunol. 2015. PMID: 25755654 Free PMC article. Review.
-
Chen H, Sameshima J, Yokomizo S, Sueyoshi T, Nagano H, Miyahara Y, Sakamoto T, Fujii S, Kiyoshima T, Guy T, Nakamura S, Moriyama M, Kaneko N, Kawano S. Chen H, et al. Front Immunol. 2023 Nov 23;14:1305783. doi: 10.3389/fimmu.2023.1305783. eCollection 2023. Front Immunol. 2023. PMID: 38077321 Free PMC article.
-
Wang S, Campos J, Gallotta M, Gong M, Crain C, Naik E, Coffman RL, Guiducci C. Wang S, et al. Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):E7240-E7249. doi: 10.1073/pnas.1608555113. Epub 2016 Oct 31. Proc Natl Acad Sci U S A. 2016. PMID: 27799536 Free PMC article.
-
Zhang Y, Zhang Z. Zhang Y, et al. Cell Mol Immunol. 2020 Aug;17(8):807-821. doi: 10.1038/s41423-020-0488-6. Epub 2020 Jul 1. Cell Mol Immunol. 2020. PMID: 32612154 Free PMC article. Review.
References
-
- Wu X, et al. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev. 2001;101:61–69. - PubMed
-
- Kuhn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science. 1995;269:1427–1429. - PubMed
-
- Watson PA, et al. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Res. 2005;65:11565–11571. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous